Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Chinese Heparin Subject Of U.S. Congress Hearing

This article was originally published in PharmAsia News

Executive Summary

The CEO of Baxter International is set to testify before a congressional hearing April 29 on the firm's contaminated heparin from China. Baxter's version of the blood thinner was linked to at least 81 deaths, the problem traced to a single source in China and said to have been deliberate. The title of the House Oversight and Investigations Subcommittee hearing is, "The Heparin Disaster: Chinese Counterfeits and American Failures." Baxter CEO Robert Parkinson and the CEO of the Chinese supplier, Scientific Protein Labs, were on the witness list. (Click here for more

Table

View full table

Tags:
Latest Headlines

Bolar Exemption India Files: Roche Blocks Alleged Infringer Of Evrysdi Patent

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

Humira Market Erosion Is Continuing As Expected, AbbVie Says

Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program

See All
UsernamePublicRestriction

Register

SC068306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By